RESUMO
Light-mediated theranostic platforms involve the use of agents (small molecules/nanomaterials), which can absorb light to produce either heat or reactive chemical species (RCS) and emit fluorescence. Such platforms are advantageous in the field of personalized medicine, as they provide enhanced diagnostic capabilities, improved therapeutic efficiencies, and can also simultaneously monitor the treatment outcomes using imaging modalities. Specifically, agents absorbing near-infrared (NIR) light can provide minimal scattering, low autofluorescence, superior spatio-temporal resolution, and deeper tissue penetration depths. Gold nanorods (GNR) and indocyanine green (ICG) are two agents known to absorb light in the NIR region. GNR can provide tunable plasmonic properties, while ICG is an FDA-approved NIR fluorophore. However, the use of ICG and GNR suffers from various limitations, such as photobleaching, non-specificity, toxicity, and aggregation in solution. To overcome these limitations, herein, we report on NIR light-activatable niosomes loaded with GNR and ICG for cancer theranostic applications. Both agents were encapsulated into non-ionic surfactant-based biocompatible niosomes to form ICG-GNR@Nio with superior loading efficiencies and enhanced properties. ICG-GNR@Nio offers excellent storage stability, photostability, elevated temperature rise and generation of reactive oxygen species (ROS) upon 1064 nm laser irradiation. Subsequently, the enhanced phototherapeutic capabilities mediated by ICG-GNR@Nio were validated in the in vitro cellular experiments. Overall, ICG-GNR@Nio-based theranostic platforms can provide a significant benchmark in the improved diagnosis and therapeutic capabilities for biomedical clinicians to tackle various diseases.
